In a retrospective analysis of 537 patients receiving ketamine intravenous therapy for depression in 178 U.S. community practices, 53.6% showed a response (at least 50% reduction in depression scores) and 28.9% achieved remission within 14-31 days after the induction phase. Among patients with suicidal ideation at baseline, 73.0% reported a reduction. A small portion of patients worsened: 8.4% experienced increased depressive symptoms and 6.0% reported increased suicidal ideation. Response rates were similar across levels of baseline depression severity. Patients who responded had about an 80% chance of sustaining that response at 4 weeks and about 60% at 8 weeks, even without maintenance infusions.
Under Oregon's regulated psilocybin program, adults who consumed an average of 27.8 mg of psilocybin showed significant improvements in depression, anxiety, and well-being 30 days after a session, including those concurrently using psychiatric medication. Of 88 participants (median age 43, 52% male, 64.8% with prior psychedelic experience), two reported symptoms of hallucinogen persisting perception disorder one day after the session, but none at 30 days. The findings suggest that legal psilocybin services can produce clinically meaningful mental health benefits.